## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.22 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Analyst consensus $145 (+23% upside). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($113.04)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million**
- Source: citybiz | 20260104T170817 | Bullish | Relevance: 100%
- Repare Therapeutics has announced that Gilead Sciences will acquire its polymerase theta (PolÎ¸) ATPase inhibitor, RP-3467, for up to $30 million. This transaction will provide Repare with a $25 million upfront payment and a potential additional $5 million, which has increased the estimated cash payment for Repare shareholders to approximately US$2.20 per common share as part of a larger acquisition by XenoTherapeutics. RP-3467 is a clinical-stage precision oncology therapeutic being evaluated in a Phase 1 trial for various advanced cancers.

**2. Verity & Verity LLC Has $30.05 Million Stake in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260103T144352 | Somewhat-Bullish | Relevance: 100%
- Verity & Verity LLC reduced its stake in Gilead Sciences (NASDAQ:GILD) by 4.6% in the third quarter, now holding 270,699 shares valued at $30.05 million. Despite insider selling totaling $16.86 million over the past 90 days, Gilead beat Q3 earnings estimates with EPS of $2.47 and revenue of $7.77 billion, and analysts maintain a "Moderate Buy" rating with a target price of $131.68. The biopharmaceutical company also recently announced a quarterly dividend of $0.79 per share, amounting to an annualized yield of 2.6%.

**3. Gateway Investment Advisers LLC Raises Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260104T122816 | Bullish | Relevance: 100%
- Gateway Investment Advisers LLC significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 57.7% in the third quarter of 2025, bringing its total holdings to 119,323 shares valued at $13.245 million. This move comes as Gilead reported strong Q3 earnings, surpassing revenue and EPS expectations, and set optimistic FY2025 guidance. The article also highlights substantial institutional buying of Gilead shares and notes some insider selling activity.

**4. SteelPeak Wealth LLC Sells 94,279 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260104T110414 | Somewhat-Bullish | Relevance: 100%
- SteelPeak Wealth LLC significantly reduced its stake in Gilead Sciences, Inc. by selling 94,279 shares in Q3, leaving them with 5,158 shares valued at $573,000. Despite this reduction, Gilead reported a Q3 EPS beat of $2.47 and projected strong FY2025 earnings, leading to a consensus "Moderate Buy" rating among analysts with a price target around $131.68. The company also announced a quarterly dividend of $0.79 per share and saw recent insider sales totaling $16.9 million.

**5. The Truth About Gilead Sciences Inc (GILD): Hidden Giant or Boomer Stock Trap?**
- Source: AD HOC NEWS | 20260105T050817 | Somewhat-Bullish | Relevance: 99%
- This article evaluates Gilead Sciences Inc (GILD) as a potential investment, contrasting its perception as a "boomer stock" with its strong fundamentals in drug pipeline, cash flow, and dividend. It highlights Gilead's established revenue from HIV and antiviral drugs, its ventures into oncology, and its appeal for income-seeking investors, while also addressing operational risks like patent cliffs and trial failures. The analysis concludes that GILD offers stability and biotech upside for long-term investors, distinguishing it from popular meme stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $151 | $147 | +3% |
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.22M) |
| Sells | 13 ($4.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $4.4M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.22 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $146.8B |
| Beta | 0.35 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.22 |
| Forward P/E | 13.5 |
| Current P/E | 14.5 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.8% to -3.1% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >4.0% for momentum thesis). Underperforming sector by 3.6pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.09% (CS: 12) | Weak |
| RSI_14 | 37.8 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 1.039x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $118.30
- **Stop Loss:** $113.04 (4.4% risk)
- **Target:** $128.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 163
- **Position Value:** $19,282.90
- **Portfolio %:** 19.28%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*